TP53 and B-cell chronic lymphocytic leukemia: In hematological malignances, AZD6738 showed activity as monotherapy in mantle cell lymphoma xenograft mouse models with ATM and p53 deficiencies [83] and in primary CLL patient-derived xenografts with 11q deletion (ATM deficient) and 17p deletion (p53 deficient) [84].